Protagonist Therapeutics Inc (PTGX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Protagonist Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 20 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 136.60 $ — 95% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 20.1% passed
- More than 10% revenue growth is expected for the coming year -68.6% failed
- Share count grows by less than 3% a year 9.0% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 32.5% failed
- Gross margin at 40% or higher and without meaningful erosion 97.3% failed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 557 m net cash passed
- Operating cash flow covers the profits of the last three years 106 m passed
- Return on capital at 15% or higher, or up versus two years ago -25.3% failed
- Insiders hold at least 10% or are net buyers 0.7% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 2.4% below the current price.
- Consensus
- Sell
- Analyst Ratings
- 10
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4.47 | 2.05 – 6.03 | 530 | 317.9% | 12 |
| 12/31/2027 | -0.19 | -2.33 – 3.70 | 185 | -104.2% | 11 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 2.11 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.98 | 348.30 | 171 | 184.40 | 77.20 | -29 | -30 |
| 2025: Q1 | -0.19 | -105.70 | 28 | -88.90 | -41.20 | 125 | 125 |
| 2025: Q2 | -0.55 | – | 6 | 33.10 | -627.00 | -29 | -30 |
| 2025: Q3 | -0.62 | – | 5 | 0.80 | -834.90 | -2 | -2 |
| 2025: Q4 | -0.70 | -135.20 | 7 | -95.60 | -596.80 | -37 | -36 |
| 2026: Q1 | 0.05 | – | 56 | 99.00 | 6.70 | -49 | -49 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -33 | -37 | -5.72 | -30 | -65 | 94 |
| 2017 | 20 | -38 | -37 | -2.09 | 4 | -102 | 164 |
| 2018 | 31 | -42 | -39 | -1.74 | -50 | -140 | 139 |
| 2019 | 0 | -81 | -77 | -2.98 | -42 | 80 | 155 |
| 2020 | 29 | -65 | -66 | -1.92 | -72 | 280 | 324 |
| 2021 | 27 | -126 | -126 | -2.71 | -108 | 300 | 348 |
| 2022 | 27 | -131 | -123 | -2.52 | -108 | 216 | 248 |
| 2023 | 60 | -94 | -79 | -1.39 | -70 | 337 | 358 |
| 2024 | 434 | 253 | 275 | 4.23 | 184 | 675 | 745 |
| 2025 | 46 | -158 | -130 | -2.05 | 58 | 615 | 670 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Protagonist Therapeutics, Inc. ist ein Forschungs- und Entwicklungsunternehmen in den USA.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 131 |
| Headquarters | Newark, CA |
| Address | 7707 Gateway Boulevard, 94560 Newark, United States |
| Phone | 510 474 0170 |
| Website | protagonist-inc.com |
| IPO Date | 11. Aug 2016 |
| ISIN | US74366E1029 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Dinesh V. Patel Ph.D. | CEO, President, Secretary & Director | 1957 |
| Asif Ali | Executive VP & CFO | 1974 |
| Arturo M. Molina FACP, M.D., M.S. | Chief Medical Officer | 1959 |
| Venkat Thalladi Ph.D. | EVP & Chief Technical Officer | – |
| Newman Yeilding M.D. | Executive VP, Chief Scientific Officer | – |
| Matthew M. Gosling J.D. | Executive VP and Chief Legal & Business Officer | 1971 |
| Carena Spivey | Executive VP & Chief Human Resources Officer | – |
| Ashok Bhandari Ph.D. | EVP & Chief Discovery Officer | 1964 |
| Carter J. King | Executive Vice President of Business Development | 1971 |
| Abha Bommireddi | Executive VP & Chief of Staff | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 20. Apr 2026 | Asif Ali | CFO | Sell | 1,750 | 105.47 | 184,573 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.